Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same author

Disrupting Notch signalling by a small molecule inhibiting dihydroorotate dehydrogenase activity.

Scientific reports·2026
Same author

Development and <i>in vivo</i> evaluation of <sup>18</sup>F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring.

Theranostics·2026
Same author

A chemoproteomic atlas of the human purine interactome for regioselective ligand discovery.

Nature communications·2026
Same author

Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.

Cancer research communications·2026
Same author

Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade.

Cancer discovery·2026

相关实验视频

Updated: Sep 17, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

介质激酶抑制剂在结肠直肠癌中的选择性和活性.

Maria J Ortiz-Ruiz1, Olajumoke Popoola1, Konstantinos Mitsopoulos1

  • 1Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.

ACS chemical biology
|July 2, 2025
PubMed
概括

选择性小分子抑制剂向循环素依赖激酶8和19 (CDK8/19) 有效调节结直肠癌中的基因表达. 这些抑制剂为研究介质激酶功能和潜在的癌症疗法提供了宝贵的工具.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.2K

相关实验视频

Last Updated: Sep 17, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.2K

科学领域:

  • 分子生物学分子生物学
  • 基因规则 基因规则
  • 癌症研究 癌症研究

背景情况:

  • 调解者复合体通过影响染色质结构和转录来调节基因表达.
  • 循环素依赖性激酶8和19 (CDK8/19) 形成一个蛋白激酶模块,控制中介体复合物的活性.
  • CDK8/19酸化RNA聚合酶II和转录因子,影响基因表达.

研究的目的:

  • 开发和验证针对CDK8/19的选择性小分子抑制剂.
  • 为了研究中间体激酶在人类结直肠癌中的作用.
  • 探索介质酶调节基因表达的机制.

主要方法:

  • 利用结合化学抑制剂和遗传淘汰模式 (CDK8/19双淘汰) 的直角方法.
  • 采用了人类结直肠细胞培养和瘤异种移植模型.
  • 进行了基蛋白质组分析和促进体记者测定.

主要成果:

  • 在结肠直肠癌模型中证明了新型氨酸和pyrazolo[3,4-b]氨酸抑制剂对CDK8/19的选择性.
  • 通过淘汰赛研究确认了抑制剂特异性和对CDK8/19的依赖性.
  • 确定了通过介质酶调节的关键基质和转录因子 (TCF/LEF,AP1).
  • 揭示了调解子单元的改变酸化,这表明了快速调节机制.

结论:

  • CDK8和CDK19在调节与瘤基因激活和结直肠癌中信号通路相关的基因表达方面是至关重要的.
  • 在这项研究中开发的选择性抑制剂是机理学研究的宝贵工具.
  • 需要进一步的研究,以充分阐明介质激酶的治疗潜力的细胞作用和调节机制.